Lexeo Therapeutics (LXEO) Assets Average (2023 - 2026)
Lexeo Therapeutics (LXEO) posted Assets Average of $259.5 million for Q1 2026, up 25.82% sequentially from $206.3 million in Q4 2025, and up 90.38% YoY from $136.3 million in Q1 2025.
Lexeo Therapeutics (LXEO) Assets Average (2023 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Assets Average for 4 years, with the latest figure at $259.5 million in Q1 2026.
- Quarterly Assets Average rose 90.38% year-over-year to $259.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.5 million (up 90.38% YoY) and the FY2025 annual result came in at $207.8 million, up 44.95% from the prior year.
- Assets Average advanced to $259.5 million in Q1 2026 per LXEO's latest filing, from $206.3 million in the prior quarter.
- Over five years, Assets Average peaked at $259.5 million in Q1 2026 and troughed at $97.3 million in Q4 2023.
- A 4-year average of $173.3 million and a median of $168.5 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average fell 25.53% in 2025, then jumped 90.38% in 2026.
- Over 4 years, Assets Average stood at $97.3 million in 2023, then soared by 64.91% to $160.4 million in 2024, then climbed by 28.59% to $206.3 million in 2025, then increased by 25.82% to $259.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $259.5 million, $206.3 million, and $160.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 252.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 252.63 Mn |
| Mar 31, 2026 | 259.52 Mn |
| Dec 31, 2025 | 206.27 Mn |
| Sep 30, 2025 | 159.96 Mn |
| Jun 30, 2025 | 150.88 Mn |
| Mar 31, 2025 | 136.32 Mn |
| Dec 31, 2024 | 160.40 Mn |
| Sep 30, 2024 | 182.94 Mn |
| Jun 30, 2024 | 202.61 Mn |
| Mar 31, 2024 | 176.51 Mn |
| Dec 31, 2023 | 97.27 Mn |